1. P647: SAFETY AND EFFECTIVENESS OF VENETOCLAX MONOTHERAPY IN R/R CLL PATIENTS WITH OR WITHOUT RISK-ASSOCIATED GENETIC MARKERS – DATA FROM THE OBSERVATIONAL VERVE STUDY. (23rd June 2022) Authors: Schwaner, I.; Hebart, H.; Losem, C.; Wolff, T.; Famulla, K.; Huelsenbeck, J.; Schmidt, B.; Nösslinger, T.; Rossi, D. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 545 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P646: EFFECTIVENESS AND SAFETY OF VENETOCLAX IN COMBINATION WITH RITUXIMAB (VENR) IN R/R CLL PATIENTS WITH OR WITHOUT RISK-ASSOCIATED GENETIC MARKERS – DATA FROM THE OBSERVATIONAL VERVE STUDY. (23rd June 2022) Authors: Schwaner, I.; Hebart, H.; Losem, C.; Wolff, T.; Famulla, K.; Huelsenbeck, J.; Schmidt, B.; Nösslinger, T.; Rossi, D. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 544 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗